Monitor the company's ability to restructure or refinance the $1.015M in past-due convertible notes and whether cash burn accelerates. The slow dairy adoption and management's candid admission of underperformance suggest limited near-term catalysts.
Price Chart
Executive Summary
PURE Bioscience reported fiscal year 2026 total revenue of $2.318M, up 5.3% from $2.202M in fiscal 2025, but net loss widened to $2.483M from $2.399M. The company's cash position improved to $569K from $334K, while total liabilities grew to $7.592M from $6.174M, with $1.015M in convertible notes past due. Management acknowledged growth did not meet expectations and dairy industry penetration has been slow.
Key Financial Metrics
Key Facts
- Fiscal year 2026 total revenue was $2,318,000, up from $2,202,000 in fiscal 2025.
- Net loss for fiscal 2026 was $2,483,000, compared to $2,399,000 in fiscal 2025.
- Net loss per share was ($0.02) for both fiscal 2026 and 2025.
- Cash and cash equivalents were $569,000 at July 31, 2026, up from $334,000 at July 31, 2025.
- Total liabilities were $7,592,000 at July 31, 2026, up from $6,174,000 at July 31, 2025.
- Convertible notes payable to related parties, current, including $1,015,000 past due, totaled $3,381,000.
- Net cash used in operations was ($1.97 million) for fiscal 2026, compared to ($2.0 million) for fiscal 2025.
- Stockholders' deficiency worsened to ($6,399,000) from ($5,116,000).
- CEO Jeff Kitchell stated growth did not meet expectations and dairy industry penetration has been slow.
- Shares outstanding increased to 130,017,569 from 111,886,473, reflecting dilution.
Financial Impact
Revenue up $116K (5.3%) but net loss increased by $84K (3.5%); cash burn remains near $2M annually; convertible debt overhang with $1.015M past due.
Risk Factors
- Convertible notes with $1.015M past due signal potential liquidity or covenant stress.
- Stockholders' deficiency of ($6.4M) and accumulated deficit of ($141.5M) indicate ongoing solvency risk.
- Dilution from convertible note conversions and share issuance (18.1M new shares in fiscal 2026).
- Management acknowledged growth did not meet expectations and dairy penetration is slow.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-049265 |
| Document: form8-k.htm | 0001493152-26-049265 |
| Document: 0001493152-26-049265-index-headers.html | 0001493152-26-049265 |
| Document: 0001493152-26-049265-index.html | 0001493152-26-049265 |
| Document: 0001493152-26-049265.txt | 0001493152-26-049265 |
| 8-K Data (Synthetic) | 0001493152-26-049265 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 29, 2026 3d ago | 8-K | $0.0751 | awaiting T+5 | awaiting T+5 | $0.0700 (+6.79%) |
Oct 20, 2026 12d ago | 8-K | $0.0800 $0.0700 | ▲ +12.50% | ▲ +12.40% | $0.0700 (+12.50%) |
Jun 15, 2026 19w ago | 8-K | $0.0600 $0.0700 | ▲ +16.67% | ▲ +18.58% | $0.0700 (+16.67%) |
May 5, 2026 25w ago | 8-K | $0.0700 $0.0700 | · 0.00% | ▲ +1.13% | $0.0700 (−0.00%) |
Mar 17, 2026 32w ago | 8-K | $0.0800 $0.0800 | · 0.00% | ▲ +2.65% | $0.0700 (−12.50%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers